...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Sao Paulo Medical Journal >Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
【24h】

Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score

机译：格里森评分低和高的前列腺癌bcl-2表达阳性率的比较

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

CONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers are not available and that effective treatment regimens forming hormone-resistant prostate cancers are yet to be developed. Among the most important regulators of apoptosis and programmed cell death is the bcl-2 gene and its related proteins. Elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy. OBJECTIVE: To characterize the expression of bcl-2 proteins as a prognostic factor in humans. DESIGN: A retrospective approach. SETTING: Urology section, Federal University of S?o Paulo. DIAGNOSTIC TEST USED: Immunohistochemical analysis using bcl-2 protein antibody and normal staining by hematoxylin-eosin. MAIN MEASUREMENTS: Prognostic relations and protein expression were evaluated considering the total sample (28) divided into two groups, high (8 to 10) and low (2 to 4), separated according to the histological differentiation grade (Gleason score) with 10 and 18 samples, respectively. RESULTS: The differentiation of grade into two groups separated according to the Gleason score in low and high types presented different bcl-2 expression (P < 0.001). CONCLUSION: The higher frequency of bcl-2 immunostaining in tumor samples was observed in association with more advanced Gleason scores and suggests that an increase in the ratio of this anti-apoptotic protein often occurs during progression of prostate cancers.
机译：上下文：多种遗传和表观遗传因素已牵涉到前列腺癌的发生和发展中。主要的困难在于临床管理源于以下事实：尚无可靠，准确的预后生物标志物，并且尚未开发出形成激素抗性前列腺癌的有效治疗方案。 bcl-2基因及其相关蛋白是最重要的细胞凋亡和程序性细胞死亡调节剂。 bcl-2蛋白水平升高可能会导致前列腺癌发展为以对化疗反应不良为特征的转移性和激素不敏感状态。目的：鉴定bcl-2蛋白的表达作为人类预后的因素。设计：一种回顾性方法。地点：圣保罗联邦大学泌尿科。使用的诊断测试：使用bcl-2蛋白抗体的免疫组织化学分析和苏木精-曙红的正常染色。主要测量：考虑预后关系和蛋白质表达，将总样本（28）分为两组（高（8至10）和低（2至4）），并根据组织学分化等级（格里森评分）将其分为10和10。分别为18个样本。结果：根据Gleason评分，低，高两种类型的年级分为两组，表现出不同的bcl-2表达（P <0.001）。结论：在肿瘤样品中观察到较高的bcl-2免疫染色频率与更先进的格里森评分相关，这表明这种抗凋亡蛋白的比例增加经常发生在前列腺癌的进展过程中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号